WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Abbott

AbbottAt Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world - in nutrition, diagnostics, medical devices and branded generic pharmaceuticals - that create more possibilities for more people at all stages of life. Today, 73,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

www.abbott.com

Abbott RSS Channel

Filters
List of articles in category Abbott
Title Published Date
Abbott completes separation of research-based pharmaceuticals business 02 January 2013
Abbott announces three-year long-term data evaluating efficacy with HUMIRA® (Adalimumab) 22 October 2012
Abbott reports double digit earnings per share growth in the third quarter 17 October 2012
Abbott's HUMIRA® (adalimumab) receives FDA approval for the treatment of ulcerative colitis 30 September 2012
Abbott announces international launch of the Absorb(TM) 25 September 2012
Abbott to collaborate with Astellas in CMV vaccine trial 06 September 2012
Abbott reports second quarter results 18 July 2012
Abbott introduces OneLab, a novel integrated web-based software platform 11 July 2012
Seven pharmaceutical companies join academic researchers to speed TB drug discovery 08 July 2012
Abbott presents phase 3 study results for investigational use of HUMIRA® (Adalimumab) 06 June 2012
Abbott to Acquire Action Pharma's Investigational Compound, AP214 04 May 2012
Abbott's investigational treatment for advanced Parkinson's disease demonstrates positive results 18 April 2012
Abbott selects AbbVie as new name for future research-based pharmaceutical company 21 March 2012
Abbott reports double-digit ongoing earnings-per-share growth in fourth quarter and full-year 2011 25 January 2012
First-of-its-kind endovascular trial of the investigational Esprit(TM) therapy 22 December 2011
Abbott and Reata Pharmaceuticals Announce Agreement 12 December 2011
PATH, Abbott and the Abbott Fund Form Innovative Partnership to Prevent Malnutrition 03 November 2011
Abbott Receives U.S. FDA Approval for Next-Generation XIENCE PRIME(TM) Drug Eluting Stent 01 November 2011
Abbott Reports Strong Ongoing Third Quarter Results 20 October 2011
Abbott to Separate into Two Leading Companies in Diversified Medical Products and Research-Based Pharmaceuticals 19 October 2011
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next
  • End
Tahmeena

Business & Industry

  • Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
  • Pfizer expands 'An Accord for a Healthier World' product offering to include full portfolio for greater benefit to 1.2 billion people in 45 lower-income countries
  • Acquisition of Neogene Therapeutics completed
  • Bayer to accelerate drug discovery with Google Cloud's high-performance compute power
  • NextPoint Therapeutics announces $80 million Series B financing co-led by Leaps by Bayer and Sanofi Ventures to advance novel immuno-oncology programs

Research & Development

  • Discovery of anti-cancer chemistry makes skullcap fit for modern medicine
  • Coordination of COVID-19 vaccine clinical trials produces a 'treasure trove' of data and a model for the future
  • Power of cancer drugs may see boost by targeting newly ID'd pathway
  • A soybean protein blocks LDL cholesterol production, reducing risks of metabolic diseases
  • 500,000 missed out on blood pressure lowering drugs during pandemic
  • Modified CRISPR-based enzymes improve the prospect of inserting entire genes into the genome to overcome diverse disease-causing mutations
  • Study identifies potential new approach for treating lupus

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  • FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
  1. You are here:  
  2. Home
  3. Abbott
  4. Abbott announces its Pandemic Defense Coalition

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.